Beta-adrenergic receptor antagonism is proinflammatory and exacerbates neuroinflammation in a mouse model of Alzheimer's Disease

Neurobiology of Disease

Volumn 146, Issue , 2020, Pages

  Evans, Andrew K ^a   Ardestani, Pooneh M ^a   Yi, Bitna ^a   Park, Heui Hye ^a   Lam, Rachel K ^a   Shamloo, Mehrdad ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's Disease; Behavior; Beta adrenergic receptor; Beta blocker; Lipopolysaccharide; Locus coeruleus; Neuroinflammation; Noradrenergic; Norepinephrine

Indexed keywords

5 [2 [[2 HYDROXY 3 [4 (1 METHYL 4 TRIFLUOROMETHYL 2 IMIDAZOLYL)PHENOXY]PROPYL]AMINO]ETHOXY]SALICYLAMIDE; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; EPINEPHRINE; ISOPRENALINE; LIPOPOLYSACCHARIDE; MABUTEROL; METOPROLOL; NORADRENALIN; PROPRANOLOL; XAMOTEROL; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ADULT; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITION; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG ANTAGONISM; DRUG POTENTIATION; EC50; ENZYME LINKED IMMUNOSORBENT ASSAY; FEAR CONDITIONING TEST; FEMALE; IC50; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROGLIA; MORRIS WATER MAZE TEST; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; AGING; ANIMAL; BRAIN; DISEASE MODEL; DRUG EFFECT; INFLAMMATION; MEMORY; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE;

ADRENERGIC BETA-ANTAGONISTS; AGING; ALZHEIMER DISEASE; ANIMALS; BRAIN; COGNITION; DISEASE MODELS, ANIMAL; INFLAMMATION; MEMORY; MICE; MICE, TRANSGENIC; MICROGLIA; NOREPINEPHRINE; RECEPTORS, ADRENERGIC, BETA;

EID: 85091649060     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2020.105089     Document Type: Article

References (51)

1. Allen, W.E., et al. Thirst-associated preoptic neurons encode an aversive motivational drive. Science 357 (2017), 1149–1155.
2. Amrhein, V., et al. Scientists rise up against statistical significance. Nature 567 (2019), 305–307.
3. Ardestani, P.M., et al. Modulation of neuroinflammation and pathology in the 5XFAD mouse model of Alzheimer's disease using a biased and selective beta-1 adrenergic receptor partial agonist. Neuropharmacology 116 (2017), 371–386.
4. Baker, J.G., The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br. J. Pharmacol. 144 (2005), 317–322.
5. Baker, J.G., The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors. Br. J. Pharmacol. 160 (2010), 1048–1061.
6. Branca, C., et al. Administration of a selective beta2 adrenergic receptor antagonist exacerbates neuropathology and cognitive deficits in a mouse model of Alzheimer's disease. Neurobiol. Aging 35 (2014), 2726–2735.
7. Cepeda, M.S., et al. Comprehensive real-world assessment of marketed medications to guide Parkinson's drug discovery. Clin. Drug Investig. 39 (2019), 1067–1075.
8. Chalermpalanupap, T., et al. Locus coeruleus ablation exacerbates cognitive deficits, neuropathology, and lethality in P301S tau transgenic mice. J. Neurosci. 38 (2018), 74–92.
9. Coutellier, L., et al. beta1-adrenergic receptor activation enhances memory in Alzheimer's disease model. Ann. Clin. Transl. Neurol. 1 (2014), 348–360.
10. Dantzer, R., et al. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 9 (2008), 46–56.
11. Duron, E., Hanon, O., Antihypertensive treatments, cognitive decline, and dementia. J. Alzheimers Dis. 20 (2010), 903–914.
12. Elenkov, I.J., et al. Modulation of lipopolysaccharide-induced tumor necrosis factor-alpha production by selective alpha- and beta-adrenergic drugs in mice. J. Neuroimmunol. 61 (1995), 123–131.
13. Elenkov, I.J., et al. The sympathetic nerve--an integrative interface between two supersystems: the brain and the immune system. Pharmacol. Rev. 52 (2000), 595–638.
14. Faizi, M., et al. Comprehensive behavioral phenotyping of Ts65Dn mouse model of down syndrome: activation of beta1-adrenergic receptor by xamoterol as a potential cognitive enhancer. Neurobiol. Dis. 43 (2011), 397–413.
15. Faizi, M., et al. Thy1-hAPP(Lond/Swe+) mouse model of Alzheimer's disease displays broad behavioral deficits in sensorimotor, cognitive and social function. Brain Behav. 2 (2012), 142–154.
16. Feinstein, D.L., et al. Noradrenergic regulation of inflammatory gene expression in brain. Neurochem. Int. 41 (2002), 357–365.
17. Feinstein, D.L., et al. Causes, consequences, and cures for neuroinflammation mediated via the locus coeruleus: noradrenergic signaling system. J. Neurochem. 139:Suppl. 2 (2016), 154–178.
18. Gliebus, G., Lippa, C.F., The influence of beta-blockers on delayed memory function in people with cognitive impairment. Am. J. Alzheimers Dis. Other Dement. 22 (2007), 57–61.
19. Goujon, E., et al. Adrenalectomy enhances pro-inflammatory cytokines gene expression, in the spleen, pituitary and brain of mice in response to lipopolysaccharide. Brain Res. Mol. Brain Res. 36 (1996), 53–62.
20. Hajjar, I., et al. Cross-sectional and longitudinal association between antihypertensive medications and cognitive impairment in an elderly population. J. Gerontol. A Biol. Sci. Med. Sci. 60 (2005), 67–73.
21. Heneka, M.T., et al. Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J. Neurosci. 26 (2006), 1343–1354.
22. Heneka, M.T., et al. Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 6058–6063.
23. Johnson, J.D., et al. Prior stressor exposure sensitizes LPS-induced cytokine production. Brain Behav. Immun. 16 (2002), 461–476.
24. Johnson, J.D., et al. Role of central beta-adrenergic receptors in regulating proinflammatory cytokine responses to a peripheral bacterial challenge. Brain Behav. Immun. 22 (2008), 1078–1086.
25. Kalinin, S., et al. Noradrenaline deficiency in brain increases beta-amyloid plaque burden in an animal model of Alzheimer's disease. Neurobiol. Aging 28 (2007), 1206–1214.
26. Kizaki, T., et al. Beta2-adrenergic receptor regulates Toll-like receptor-4-induced nuclear factor-kappaB activation through beta-arrestin 2. Immunology 124 (2008), 348–356.
27. Mather, M., Harley, C.W., The locus coeruleus: essential for maintaining cognitive function and the aging brain. Trends Cogn. Sci. 20 (2016), 214–226.
28. McNamee, E.N., et al. Noradrenaline acting at central beta-adrenoceptors induces interleukin-10 and suppressor of cytokine signaling-3 expression in rat brain: implications for neurodegeneration. Brain Behav. Immun. 24 (2010), 660–671.
29. Mittal, S., et al. beta2-Adrenoreceptor is a regulator of the alpha-synuclein gene driving risk of Parkinson's disease. Science. 357 (2017), 891–898.
30. Nguyen, T.V., et al. Small molecule p75NTR ligands reduce pathological phosphorylation and misfolding of Tau, Inflammatory Changes, Cholinergic Degeneration, And Cognitive deficits in AbetaPPL/S transgenic mice. J. Alzheimers Dis. 42 (2014), 459–483.
31. O'Carroll, R.E., et al. Stimulation of the noradrenergic system enhances and blockade reduces memory for emotional material in man. Psychol. Med. 29 (1999), 1083–1088.
32. Papandreou, V., et al. Adrenergic effect on cytokine release after ex vivo healthy Volunteers’ whole blood LPS stimulation. Inflammation 39 (2016), 1069–1075.
33. Paran, E., et al. Cognitive function and antihypertensive treatment in the elderly: a 6-year follow-up study. Am. J. Ther. 17 (2010), 358–364.
34. Perry, V.H., et al. Systemic infections and inflammation affect chronic neurodegeneration. Nat. Rev. Immunol. 7 (2007), 161–167.
35. Qin, L., et al. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia. 55 (2007), 453–462.
36. Ryan, K.J., et al. Complementary anti-inflammatory actions of the beta(2)-adrenoceptor agonist clenbuterol and the glucocorticoid dexamethasone in rat brain. J. Neuroimmunol. 232 (2011), 209–216.
37. Ryan, K.M., et al. Clenbuterol activates the central IL-1 system via the beta2-adrenoceptor without provoking inflammatory response related behaviours in rats. Brain Behav. Immun. 56 (2016), 114–129.
38. Sara, S.J., The locus coeruleus and noradrenergic modulation of cognition. Nat. Rev. Neurosci. 10 (2009), 211–223.
39. Saxe, M.D., et al. Ablation of hippocampal neurogenesis impairs contextual fear conditioning and synaptic plasticity in the dentate gyrus. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 17501–17506.
40. Schmittgen, T.D., Livak, K.J., Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 3 (2008), 1101–1108.
41. Song, S., et al. Loss of brain norepinephrine elicits neuroinflammation-mediated oxidative injury and selective caudo-rostral neurodegeneration. Mol. Neurobiol. 56 (2019), 2653–2669.
42. van der Poll, T., et al. Noradrenaline inhibits lipopolysaccharide-induced tumor necrosis factor and interleukin 6 production in human whole blood. Infect. Immun. 62 (1994), 2046–2050.
43. Wang, J., et al. Carvedilol as a potential novel agent for the treatment of Alzheimer's disease. Neurobiol. Aging, 32, 2011 2321–12.
44. Wang, J., et al. Galphai is required for carvedilol-induced beta1 adrenergic receptor beta-arrestin biased signaling. Nat. Commun., 8, 2017, 1706.
45. Wasserstein, R.L., et al. Moving to a world beyond “p < 0.05”. Am. Stat. 73 (2019), 1–19.
46. Weinshenker, D., Functional consequences of locus coeruleus degeneration in Alzheimer's disease. Curr. Alzheimer Res. 5 (2008), 342–345.
47. Wisler, J.W., et al. A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 16657–16662.
48. Wohleb, E.S., et al. Peripheral innate immune challenge exaggerated microglia activation, increased the number of inflammatory CNS macrophages, and prolonged social withdrawal in socially defeated mice. Psychoneuroendocrinology 37 (2012), 1491–1505.
49. Yang, J.H., et al. Norepinephrine differentially modulates the innate inflammatory response provoked by amyloid-beta peptide via action at beta-adrenoceptors and activation of cAMP/PKA pathway in human THP-1 macrophages. Exp. Neurol. 236 (2012), 199–206.
50. Yi, B., et al. Discovery of novel brain permeable and G protein-biased beta-1 adrenergic receptor partial agonists for the treatment of neurocognitive disorders. PLoS One, 12, 2017, e0180319.
51. Zhang, Y., et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J. Neurosci. 34 (2014), 11929–11947.